Date: Thursday, February 27th, 2020
Time: 1:00 PM EDT / 10:00 AM PDT
In order to ensure the safety, efficacy and quality of human and veterinary drugs, biological products, and medical devices, the FDA has stepped up its regulatory focus on data integrity significantly over the last several years, leading to numerous regulatory actions (e.g., warning letters, import alerts, and consent decrees).
FDA enforcement actions can result in significant consequences including facility shutdown, import and/or distribution bans, remediation costs, delayed/denied drug approvals, damaged reputation and recalls. In addition, data integrity violations can result in loss of trust by the FDA, leading to more frequent and in-depth inspections in the future.
Given the FDA’s current focus on data integrity, data integrity assessments should be included in your organization’s quality management system (QMS) as part of cGMP audit programs. In this webinar, we will discuss best practice recommendations for conducting data integrity assessments that help to ensure compliance with FDA regulations.
Some of the topics covered in this webinar include: